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1. Introduction 
Cardiovascular disease, mostly coronary artery disease (CAD), remains an important cause 
of morbidity and mortality in patients with any degree of renal dysfunction. Presently, 
according to the United States Renal Data System, the size of the population with chronic 
kidney disease (CKD) stage V reached a new high in 2008, with almost 550,000 patients 
under treatment (U.S. Renal Data System, 2010). Sadly, it is expected that half of them will 
die from cardiovascular disease; moreover, it is noteworthy that even patients with less 
advanced stages of CKD are at greater risk of death from CAD than of reaching the final 
stages of renal failure that would eventually require renal replacement therapy (Sarnak et 
al., 2003). In these patients, about 50% to 60% of all cardiovascular deaths are due to acute 
myocardial infarction, sudden death, or ischemic heart disease (Herzog et al., 2008). 
The interplay between CKD and CAD is a very complex one and can only be partly 
explained by the fact that patients with CKD share many of the so-called traditional risk 
factors also linked to CAD, such as long-standing diabetes, hypertension, low levels of 
HDL-cholesterol, and hypertriglyceridemia (McCullough, 2002a). Additionally, a pro-
inflammatory state and high oxidative stress levels are usually seen in patients with 
advanced CKD, which may contribute to accelerated atherosclerosis, plaque instability, 
acute coronary syndromes, and myocardial fibrosis (Yerkey et al., 2004). The result of this 
clustering of traditional and nontraditional risk factors may explain the epidemiological 
observation that patients with CKD stage V have more than a 10-fold increased risk of death 
from CAD than a patient with 5 Framingham risk scores (McCullough, 2002b).  
The prevalence of CAD in CKD patients undergoing dialysis varies with such factors as age, 
diabetic status, time of follow-up, and the diligence with which CAD is investigated. In a 
group of 4,024 new dialysis patients, including 44% with diabetes, 32% had a history of 
CAD (Foley, 2003), which is conceivably more than 3 times the figure corresponding to CAD 
in the general population (Levey & Eknoyan, 1999). The prevalence of angiographically 
confirmed CAD, on the other hand, defined as luminal reduction >50%, ranges from 24% in 
low-risk patients to 85% in older, diabetic patients (Goldsmith & Covic, 2001). Nevertheless, 
most of these data originated from studies in which coronary angiography was performed 
only in patients with clinical evidence and/or noninvasive studies suggestive of CAD, 
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leaving out patients in whom asymptomatic, undiagnosed, significant CAD might be 
already present; therefore, the actual prevalence of CAD might even be higher. 
Adding to the importance of CAD in patients with CKD, observational data also show that 
CAD remains a significant clinical problem even if a patient undergoes successful kidney 
transplantation (Aakhus et al., 2004). The annual risk of CVD death is 3.5% to 5% in renal 
transplant recipients, which is 50-fold higher than that in the general population (Ojo, 2006). 
Acute coronary syndrome is highly prevalent in the early posttransplant period, and on 
average, CVD mortality accounts for 30% and 75% of early and late posttransplant deaths, 
respectively. 
Therefore, coronary angiography is a valuable tool, very often used in patients with CKD 
both in the acute as well as in the chronic setting of CAD, for the purpose of either the 
diagnosis of, or the treatment of CAD by means of percutaneous coronary intervention. The 
major challenges with coronary angiography relate to when is it appropriate to perform it as 
part of the cardiovascular assessment in patients with CKD and what are the risks 
associated with the procedure. The ultimate management of CAD, should it be found after 
the diagnostic procedure, is beyond the scope of this chapter. 
2. Screening for coronary artery disease in patients with CKD 
Based on the above considerations, screening for the presence and severity of CAD in 
patients with CKD, and especially in those being considered for renal transplantation, is a 
fundamental step during routine cardiovascular risk assessment; in the setting of kidney 
transplantation, for instance, numerous studies indicate that not only are the majority of 
serious cardiovascular events in renal transplant recipients related to CAD but also these 
events tend to occur during the first few months following transplant (Kahwaji et al., 2011). 
The last observation strongly suggests that relevant CAD could have been missed before 
patients were actually included on renal transplant waiting lists, although they had been 
screened for it during routine pretransplant workups according to current guidelines. 
According to the American Society of Transplantation recommendations (Kasiske et al., 
2001), patients with diabetes, a prior history of ischemic heart disease or an abnormal ECG, 
or age 50 years should be considered at high risk for CAD and referred for a cardiac stress 
test, and only in those with a positive stress test, for coronary angiography. 
This strategy, however, is under dispute for the now recognized reduced sensitivity and 
specificity of noninvasive testing in renal patients compared with that in the general 
population (Marwick et al., 1990; Schmidt et al., 2001; Welsh et al., 2011), a finding that 
prompted many investigators to recommend direct diagnostic coronary angiography in 
high-risk patients. In agreement with the last view, in a previous study, our group showed 
that significant CAD, as defined by coronary angiography, was the best predictor of 
cardiovascular events compared with radionuclide myocardial perfusion study or 
dobutamine-atropine stress echocardiography in renal transplant candidates (De Lima et al., 
2003), even taking into account that coronary angiography is an expensive, invasive 
procedure, not free from complications. However, in the same investigation, we also found 
that the prevalence of significant CAD was less than 50%, suggesting a need for better 
screening mechanisms that could identify high-risk individuals in whom coronary 
angiography could be avoided without incurring an increased risk of future events. 
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2.1 The challenge of referring patients with CKD for coronary angiography 
Tables 1 and 2 show the most recent guidelines for coronary angiography to establish the 
diagnosis in patients with suspected angina and for risk stratification in patients with chronic 
stable angina, respectively (Fraker Jr et al., 2007).   
Invasive coronary angiography has received a Class I indication for patients with known or 
possible angina pectoris who have survived sudden cardiac death. For risk stratification in 
patients with chronic stable angina, coronary angiography should be performed in: a) 
patients with disabling (Canadian Cardiovascular Society classes III and IV) stable angina 
despite medical therapy; b) patients with high-risk criteria on noninvasive testing; c) 
patients with angina and symptoms and signs of heart failure; d) patients with clinical 
characteristics indicating a high likelihood of severe CAD.  
 
Coronary angiography is 
indicated to establish the 
diagnosis of CAD in patients with 
suspected angina in those with… 
Level of 
Evidence 
Comment for Patients with CKD 
Known or possible angina pectoris 
who have survived sudden cardiac 
death 
B 
Survival rates much lower than rates 
for the general population 
Table 1. Class I indication of the AHA/ACC Guidelines for coronary angiography to 
establish a diagnosis in patients with suspected angina in the general population. Modified 
from Fraker Jr, et al. (2007). 
 
Coronary angiography is 
indicated for risk stratification in 
patients with chronic CAD in 
those with… 
Level of 
Evidence 
Comment for Patients with CKD 
Disabling chronic stable angina 
despite medical therapy 
B 
Uncommon clinical presentation for 
patients with CKD 
High-risk criteria on noninvasive 
testing regardless of angina 
severity 
B 
Lower sensitivity than that in the 
general population  
Angina who have survived sudden 
cardiac death or serious ventricular 
arrhythmia 
B 
Survival rates much lower than those 
in the general population 
Angina and symptoms and signs of 
congestive heart failure 
C 
May be confused with hypertensive 
cardiomyopathy, fluid overload,  
subdialysis 
Clinical characteristics that indicate 
a high likelihood of severe CAD  
C 
Lower specificity than that in the 
general population 
Table 2. Class I indications of the AHA/ACC Guidelines for coronary angiography for risk 
stratification in patients with chronic stable angina. Modified from Fraker Jr, et al. (2007). 
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Although these guidelines have been extensively tested and validated in the general 
population, for patients with CKD the data supporting that approach is less robust. The 
main pitfalls of applying the same criteria recommended for patients with normal renal 
function to patients with CKD are briefly described below. 
2.1.1 Clinical presentation 
Although angina pectoris is usually a reliable indicator of the presence of CAD in the 
general population, it is not so among patients with CKD, particularly in the more advanced 
stages of renal failure. For instance, chest pain is commonly observed in the dialysis 
population; nevertheless, its characteristics make the discomfort often described as 
“atypical,” and the pain does not correlate with the presence of significant CAD. In fact, 
fewer than 50% of dialysis patients with acute myocardial infarction present with chest pain, 
which likely explains why myocardial infarction is infrequently suspected on admission 
(Herzog et al., 2007). Reasons for the different presentations of ischemia are not well 
understood but may be related to associated diabetic or uremic neuropathy. Diagnosis of 
ischemia is further complicated by the fact that other symptoms of ischemia, such as 
dyspnea on exertion, fatigue, and hypotension, are common in dialysis patients and may be 
attributed to dialysis-related factors, such anemia, volume overload, acidosis, non-
compliance with fluid intake or dialysis or to ultra-filtration during dialysis (Sosnov et al., 
2006). Furthermore, silent ischemia occurs frequently in patients with CKD.  
We previously found that, in a group of high-risk renal transplant candidates who 
underwent coronary angiography per protocol, regardless of symptoms, the prevalence of 
significant CAD was 40% in patients with, and 58% in patients without, angina (De Lima et 
al., 2003). Disabling symptoms, even in the presence of significant and extensive CAD, are 
quite uncommon in patients with CKD. 
2.1.2 Noninvasive testing 
2.1.2.1 Resting and exercise electrocardiogram 
The interpretation of resting and exercise electrocardiograms for the diagnosis of CAD in 
patients on dialysis is often hampered by the presence of concurrent left ventricular 
hypertrophy, anemia, and electrolyte disturbances that may cause electrocardiographic 
changes resembling those of ischemia (Sharma et al., 2007). Also, most patients with CKD 
have poor physical stamina, limiting the utility of exercise electrocardiography as a 
diagnostic tool. The overall specificity and sensitivity of both tests for the diagnosis of CAD 
are lower (<50%) in patients with CKD than in the general population. 
2.1.2.2 Myocardial perfusion assessment 
Dipyridamole radionuclide stress testing with single-photon emission tomography (SPECT) has 
been widely used as a screening test for CAD in patients with a variety of clinical conditions. 
The reported specificity and sensitivity of the test are close to 70% and 80%, respectively. 
Among patients with CKD, however, the results are highly variable with sensitivity often <60% 
compared to that of coronary angiography (Holley et al., 1991; Sharma et al., 2007). The reasons 
for the unexpected low sensitivity and great variability of cardiac scintigraphy in patients with 
CKD are unclear but may reflect the increased levels of circulating adenosine, reduced coronary 
flow reserve, or left ventricular hypertrophy. Combined dipyridamole-exercise thallium 
imaging reportedly increases the sensitivity and specificity of the test.  
Dobutamine-atropine stress echocardiography has been associated with better and more 
consistent results for detecting significant (>70%) coronary stenosis in patients with CKD, 
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with a sensitivity and negative predictive value between 70% and 80% (Herzog et al., 1999; 
Ferreira et al., 2007). However, the utility of this test is limited, because dobutamine often 
increases blood pressure, causing interruption of the test in about 15% of patients.  
Until a few years ago, magnetic resonance imaging (MRI) had been used for assessment of 
myocardial function and detection of myocardial ischemia and scar tissue in patients with 
CKD (Andrade et al., 2009). Myocardial stress perfusion studies performed with MRI  
adequately detected CAD, and there was a good correlation between these results and those 
from coronary angiography and radionuclide studies (Andrade et al., 2004). Unfortunately, 
further development of this imaging modality was halted, because of the description of a 
serious complication related to the use of gadolinium-based contrast media in patients with 
CKD, called nephrogenic systemic fibrosis (Grobner, 2006). Thus, starting in 2007, the 
United States Food and Drug Administration issued a boxed warning about this 
progressive, debilitating and, occasionally fatal condition recommending that the use of 
gadolinium-based contrast agents should be avoided in patients with acute or chronic renal 
insufficiency with a glomerular filtration rate < 30mL/min/1.73m2. 
2.1.2.3 Coronary angiotomography 
Multidetector-row computed tomography (MDCT) has been recently applied to the 
detection of CAD in patients with ESRD (Rosário et al., 2010). This method allows not only 
the detection of coronary calcifications but also the detailed visualization of the arterial wall 
and lumen, and therefore, may become an alternative to coronary angiography. Experience 
with this method in patients with CKD is still very limited. 
2.1.2.4 Clinical implications 
Thus, referring patients with CKD for coronary angiography is not an easy task (De Lima et 
al., 2010; Lentine et al., 2010). One could be very “conservative,” only referring patients with 
overt, unequivocal symptoms of angina or extensive myocardial ischemia on noninvasive 
testing to undergo coronary angiography. 
This approach would most likely yield a prohibitively large number of “false negatives,” 
meaning that many patients with significant CAD will be deemed free of disease. It is quite 
easy to see the clinical implications of such an approach, especially for renal transplant 
candidates. Alternatively, one could be very “aggressive” and refer all patients with CKD 
stages IV or V for coronary angiography. We would be able to diagnose every single patient 
with CAD in adopting this strategy. The downside is that coronary angiography is a 
somewhat risky, costly procedure and as many as 50% to 60% of all patients will have no 
significant CAD at all and, therefore, will not be further referred for coronary interventions 
(percutaneous or surgical). Finally, patients still not on renal replacement therapy might not 
only not benefit from this strategy but might also have worsening of their residual renal 
function because of the contrast-induced nephropathy.  
As a matter of fact, it is still unclear whether the benefits outweigh the harms of routine 
screening and prophylactic revascularization to prevent coronary artery disease (CAD) in 
asymptomatic kidney transplant candidates. To help clarify that issue, an ongoing 
randomized clinical trial is being performed to study the effect of CAD screening on major 
adverse cardiac events (Kasiske et al., 2011). 
3. In whom should coronary angiography be performed? 
The same indications presented in Tables 1 and 2 should be applied to patients with CKD. 
The greatest challenge facing the clinical cardiologist called upon to assess a patient with 
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CKD regarding the presence and severity of CAD is, based on the previous considerations, 
which additional patients should be referred for coronary angiography, especially those 
asymptomatic patients being assessed before renal transplantation. 
In a previous study, we sought to determine the clinical predictors more closely related to 
CAD in 301 renal transplant candidates treated by hemodialysis (Gowdak et al, 2007). CAD 
(> 70% stenosis) was found in 45% of patients, and the clinical variables significantly 
associated with CAD were diabetes, peripheral vascular disease, and previous myocardial 
infarction. More important, the prevalence of CAD increased with the number of clinical 
predictors from 26% (none) to 100% (all present), while the incidence of events increased 2-, 
4-, and 6-fold in those with diabetes, peripheral vascular disease, or previous myocardial 
infarction, respectively (p < .0001). This approach would allow reducing the prevalence of 
unnecessary angiography from 55% (when all patients undergo angiography) to 26%. 
However, we believe that missing the diagnosis of CAD in one-fourth of patients is still not 
totally satisfactory. 
Another approach should be to restrict the use of coronary angiography as a predictive tool 
of cardiovascular events in patients with CKD in which this strategy is powerful enough to 
discern between patients at high- and low-risk, comparatively to either clinical stratification 
alone or to noninvasive testing. We compared the efficacy of clinical stratification, 
noninvasive testing, and coronary angiography in predicting cardiovascular events in 
patients with CKD being considered as potential renal transplant candidates (De Lima et al., 
2006; Gowdak et al., 2008). We were able to show that, for patients considered at low-risk for 
CAD (age < 50 years, with no diabetes, and no history of cardiovascular disease), additional 
noninvasive or invasive testing, added no capability in predicting cardiovascular events 
beyond that given by clinical stratification. On the other hand, for patients at high-risk for 
CAD, defined by the presence of any 2 risk factors combined (age  50 years or diabetes or 
cardiovascular disease), noninvasive testing failed to identify patients at higher risk for 
cardiovascular events; indeed, the finding of significant CAD by angiography (luminal 
stenosis  70%) was the strongest predictor of events. For patients at intermediate-risk for 
CAD, defined by the presence of any single risk factor alone, noninvasive testing was a good 
tool in identifying patients at higher risk of events, should an abnormal myocardial 
perfusion scan be found. Figure 1 shows the proposed algorithm for risk stratification of 
CAD in renal transplant candidates. 
4. Contrast-induced Acute Kidney Injury 
Very often, the highlighted importance of coronary angiography for the diagnosis and/or 
management of CAD in patients with CKD is offset by the possibility of contrast-induced 
acute kidney injury (AKI) that may follow the use of any iodinated contrast media. 
Contrast-induced AKI is a common and potentially serious complication after the 
administration of contrast media in patients at risk for acute renal injury (McCullough, 
2008). Unfortunately, the most important risk factor for contrast-induced AKI is an already 
compromised baseline renal function. The knowledge that not only contrast-induced AKI 
adversely affects the short- and long-term prognosis but also implies greater health costs 
prompted cardiologists to be particularly careful whenever coronary angiography is 
recommended to patients with any degree of CKD. 
Many definitions currently exist in practice regarding contrast-induced AKI; it can be 
simply defined as an increase in serum creatinine (SCr) occurring within the first 24h after 
contrast exposure and peaking up to 5 days afterwards. The rise in Scr can be expressed 
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either in absolute terms (0.5 to 1.0mg/dL) or as a proportional rise in SCr of 25% to 50% 
above the baseline value (Gleeson & Bulugahapitiya, 2004). 
 
 
Fig. 1. Proposed algorithm for coronary angiography in patients with CKD awaiting renal 
transplantation. 
RENAL TRANSPLANT CANDIDATES
Clinical stratification following the 
American Society of Transplantation 
Guidelines 
1. Age  50 years 
2. Diabetes 
3. History of cardiovascular disease 
NUMBER OF RISK FACTORS
ZERO TWOONE THREE 
LOW RISK INTERMEDIATE
RISK
HIGH RISK
NON-INVASIVE 
TESTING
No further 
testing 
NEGATIVE POSITIVE
CORONARY ANGIOGRAPHY 
NEGATIVE POSITIVE 
Treat according to the current 
guidelines 
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The increase in SCr seen in patients with contrast-induced AKI is associated with a 
significant increase in the risk of death. In a large retrospective study comprising over 16,000 
patients undergoing procedures, those who developed contrast-induced AKI had a 5.5-fold 
increased risk of death during hospitalization (Levy et al., 1996). Another study with more 
than 7,000 patients confirmed the short-term worse prognosis in patients with AKI but 
extended the greater risk of death up to 5 years after the procedure: the mortality rates at 1 
year after development of contrast-induced AKI (12.1%) and at 5 years (44.6%) were higher 
compared with rates of 3.7% and 14.5%, respectively, in patients who did not develop 
contrast-induced AKI, indicating that the increased risk of death persisted in the long term 
(Rihal et al., 2002). 
Besides the increased mortality, contrast-induced AKI also poses a high morbidity risk. Its 
occurrence has been linked to late cardiovascular events after percutaneous coronary 
intervention (such as myocardial infarction), bleeding requiring transfusion, and vascular 
complications. As a consequence of more serious adverse events, the in-hospital stay is 
longer with an estimated US$10,000 to US$12,000 added to the final bill during the first year 
(Subramanian et al., 2007). 
4.1 Pathophysiology of contrast-induced Acute Kidney Injury 
Centrally to the pathophysiology of contrast-induced AKI is the presence of a reduced 
nephron mass, a hallmark of chronic kidney disease. It has already been demonstrated that 
in patients with CKD, defined by an estimated glomerular filtration rate < 
60mL/min/1.73m2, there is a considerable loss of nephron units, making the residual renal 
function prone to further declines with renal insults (Figure 2). When serum creatinine or 
eGFR is unavailable, then a survey may be used to identify patients at higher risk than the 
general population for contrast-induced AKI. Iodinated contrast, after causing a brief 
(minutes) period of vasodilation, causes sustained (hours to days) intrarenal 
vasoconstriction and ischemic injury. The ischemic injury sets off a cascade of events largely 
driven by oxidative injury causing death of renal tubular cells. If a sufficient mass of 
nephron units is affected, then a recognizable rise in serum creatinine will occur. Any 
superimposed insult, such as sustained hypotension in the catheterization laboratory, micro-
showers of atheroembolic material from catheter exchanges or the use of intraaortic balloon 
counterpulsation, or a bleeding complication can amplify the injury processes occurring in 
the kidney (McCullough et al., 2006a). 
Renal function must be assessed before administration of contrast medium so appropriate 
caution may be exercised to avoid additional risks. The National Kidney Foundation Kidney 
Disease Outcome Quality Initiative recommends that clinicians use an eGFR calculated from 
the SCr as an index of renal function rather than using SCr in stable patients. In such a 
situation when an eGFR cannot be obtained prior to the procedure, clinicians should inquire 
about risk markers for AKI after iodinated contrast (Table 3). 
The presence of multiple contrast-induced AKI risk factors in the same patient or high-risk 
clinical scenarios can create a very high risk (50%) for contrast-induced AKI and (15%) 
acute renal failure requiring dialysis after contrast exposure. 
In the setting of emergency procedures, where the benefit of very early imaging outweighs 
the risk of waiting, the procedure can be performed without knowledge of serum creatinine 
or eGFR. 
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Risk markers for contrast-induced acute kidney injury 
previous renal disease diabetes mellitus 
prior renal surgery hypertension 
proteinuria gout 
use of nephrotoxic drugs, such as 
nonsteroidal anti-inflammatory agents 
 
Table 3. A brief 7-item survey to identify patients at higher risk for AKI. 
 
 
Fig. 2. Postulated pathophysiology of contrast-induced AKI (McCullough, 2008). 
4.2 Contrast medium use 
In patients at increased risk for contrast-induced AKI undergoing intraarterial 
administration of contrast, ionic high-osmolality agents pose a greater risk for contrast-
induced AKI than low-osmolality agents (Barrett & Carlisle, 1993). Red blood cell 
deformation, systemic vasodilation, intrarenal vasoconstriction, as well as direct renal 
tubular toxicity are all more common in contrast agents with osmolality greater than that of 
blood.  
Current evidence suggests that for intraarterial administration in high-risk patients with 
CKD, particularly those with diabetes mellitus, nonionic, iso-osmolar contrast is associated 
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with the lowest risk of contrast-induced AKI. Iodixanol (an iso-osmolar contrast media) has 
been shown to have the lowest risk for contrast-induced AKI in patients with CKD and 
diabetes mellitus compared with low-osmolar contrast media (McCullough et al. 2006b). The 
American College of Cardiology/American Heart Association guidelines for the management of 
acute coronary syndromes in patients with CKD listed the use of iso-osmolar contrast media 
as a class I, Level of Evidence: A recommendation. The National Kidney Foundation Kidney 
Disease Outcome Quality Initiative guidelines have also recommended use of iso-osmolar 
contrast media in renal dialysis patients to minimize the chances of volume overload and 
complications before the next dialysis session. 
Higher contrast volumes (100 mL) are associated with higher rates of contrast-induced 
AKI in patients at risk. However, even small (30 mL) volumes of iodinated contrast in 
very high-risk patients can cause contrast-induced AKI and acute renal failure requiring 
dialysis, suggesting the absence of a threshold effect (Manske et al., 1990). As a general 
rule, the volume of contrast received should not exceed twice the baseline level of eGFR in 
mL.  
Finally, intraarterial administration of iodinated contrast appears to pose a greater risk of 
contrast-induced AKI above that with intravenous administration. 
4.3 Strategies to further reduce the risk of contrast-induced Acute Kidney Injury 
4.3.1 Volume expansion 
Adequate intravenous volume expansion with isotonic crystalloid (1.0–1.5 mL/kg/h) for 3–
12 h before the procedure and continued for 6–24 h afterwards can lessen the probability of 
contrast-induced AKI in patients at risk (Mueller et al., 2002). Achieving a good urine output 
(150 mL/h) in the 6h after the procedure has been associated with reduced rates of AKI in 
one study. The data on oral as opposed to intravenous volume expansion as a contrast-
induced AKI prevention measure are insufficient. 
4.3.2 Pharmacologic agents 
No adjunctive medical or mechanical treatment has been proven to be efficacious reducing 
the risk of AKI after exposure to iodinated contrast. With iodinated contrast, the 
pharmacologic agents tested in small trials that deserve further evaluation include the 
antioxidants ascorbic acid and N-acetylcysteine (NAC), aminophylline/theophylline, 
statins, and prostaglandin E1. 
4.3.2.1 Ascorbic acid 
Only ascorbic acid has been tested in a multicenter, blinded, placebo-controlled trial (n=231) 
and been shown to reduce rates of contrast-induced AKI. The dose of ascorbic acid (vitamin 
C over the counter) used in this trial was 3g orally the night before and 2g orally twice a day 
after the procedure (Spargias et al., 2004).  
4.3.2.2 N-acetylcysteine 
Although popular, NAC has not been consistently shown to be effective. Nine meta-
analyses have been published, all documenting the significant heterogeneity between 
studies and pooled odds ratios for NAC approaching unity (Stacul et al., 2006). Importantly, 
only in those trials where NAC reduced SCr below baseline values because of decreased 
skeletal muscle production did renal injury rates appear to be reduced.  
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However, NAC as an antioxidant has been shown to lower rates of AKI and mortality after 
primary PCI in 1 trial. The recently published REMEDIAL (Renal Insufficiency Following 
Contrast Media Administration) trial suggested that the use of volume supplementation 
with sodium bicarbonate together with NAC was more effective than NAC alone in 
reducing the risk of AKI (Briguori et al., 2007; Brown et al., 2009). Dosing of NAC has varied 
in the trials; however, the most successful approach has been with 1,200 mg orally twice a 
day on the day before and after the procedure. 
4.3.2.3 Other agents 
Fenoldopam, dopamine, calcium-channel blockers, atrial natriuretic peptide, and L-arginine 
have not been shown to be effective in the prevention of contrast-induced AKI. Furosemide, 
mannitol, and an endothelin receptor antagonist are potentially detrimental (Stacul et al., 
2006). 
In general, cardiovascular patients undergoing procedures with iodinated contrast have 
either high risk for atherosclerosis or have the anatomic presence of disease. Therefore, the 
vast majority of patients should be on statin therapy with a common low-density lipoprotein 
cholesterol target of <70 mg/dL. Several studies have demonstrated that patients continuing 
on statins during cardiovascular procedures including PCI and coronary artery bypass 
grafting have lower rates of AKI (Khanal et al., 2005). All small, randomized trials published 
to date support this concept as well. Preservation of endothelial function at the level of the 
glomerulus and reductions in systemic inflammatory factors are postulated mechanisms by 
which statins may have renoprotective effects. 
4.3.2.4 Dialysis and hemofiltration 
Prophylactic hemodialysis or hemofiltration has not been validated as an effective strategy, 
even when carried out within 1 h or simultaneously with contrast administration. 
Hemofiltration, however, performed 6 h before and 12 to 18 h after contrast deserves 
consideration, given reports of reduced mortality and need for hemodialysis in the 
postprocedure period in very high-risk patients (Marenzi et al., 2003).  
4.3.2.5 Withdrawal of additional nephrotoxic drugs 
Despite the lack of more robust data in this area, it is a reasonable practice to withhold 
nonsteroidal anti-inflammatory drugs, calcineurin inhibitors, high-dose loop diuretics, 
aminoglycosides, and other nephrotoxic agents if possible for several days before contrast 
exposure (McCullough, 2008). It is routine practice to withhold metformin before all contrast 
procedures, not because metformin itself is nephrotoxic but because in the setting of AKI if 
metformin is continued, lactic acidosis can develop leading to systemic complications and 
death. As a general rule, metformin should not be restarted until the clinician is confident 
that the patient has not developed AKI. 
4.4 Management of patients receiving iodinated contrast media 
An integrated proposed algorithm for the management of patients receiving iodinated 
contrast media is presented in Figure 3. Since there are no approved pharmaceutical agents 
for the prevention of this complication, the practitioner should be cautious with the use of 
any of the drugs suggested. We also recommend that all patients at risk for contrast-induced 
AKI should have follow-up serum creatinine and electrolyte monitoring daily while in the 
hospital, and then at 48 to 96h after discharge. 
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Fig. 3. Proposed algorithm for management of contrast-induced AKI (McCullough, 2008). 
5. Conclusion 
Patients with chronic kidney disease are at high-risk for CAD and, therefore, coronary 
angiography is very often needed to establish the diagnosis and severity of CAD. The major 
challenges in this regard are how to select those patients more likely to have significant 
CAD, in the absence of typical symptoms suggestive of CAD or myocardial perfusion 
defects disclosed by noninvasive testing. Moreover, the possibility of contrast-induced acute 
kidney injury should signal the need for a careful and more judicious decision-making 
approach by the cardiologist, working in tandem with the nephrologist, when trying to 
establish the risk-benefit ratio for each patient being considered for invasive assessment. 
Having decided that an invasive procedure is clearly needed, all preventive and therapeutic 
measurements should be applied to minimize the risk of worsening residual renal function.      
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